Clinical Trials
6 trialsNCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT02742727 2016-12-06
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown